Skip to main content
  • Book
  • © 2017

Rare Diseases Epidemiology: Update and Overview

Editors:

(view affiliations)
  • Contributors and Authors with Unique Experiences in Rare Diseases Research and Orphan Products Development

  • Contributors include leading patient advocates, foundation leaders, research investigators, regulatory agency decision makers, and bio-pharmaceutical industry leaders

  • Multi-National Government Program and Policy Leaders

  • Leaders in Global Collaboration Efforts

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1031)

Buying options

eBook
USD 219.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-67144-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 279.99
Price excludes VAT (USA)
Hardcover Book
USD 279.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (34 chapters)

  1. Front Matter

    Pages i-xxxvi
  2. Introduction

    1. Front Matter

      Pages 1-1
  3. Rare Diseases Diagnosis

    1. Front Matter

      Pages 23-23
    2. Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases Lacking a Diagnosis

      • Domenica Taruscio, Giovanna Floridia, Marco Salvatore, Stephen C. Groft, William A. Gahl
      Pages 25-38
    3. Intellectual Disability & Rare Disorders: A Diagnostic Challenge

      • Malin Kvarnung, Ann Nordgren
      Pages 39-54
    4. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework

      • Gareth Baynam, Faye Bowman, Karla Lister, Caroline E. Walker, Nicholas Pachter, Jack Goldblatt et al.
      Pages 55-94
  4. Registries, Natural History of Rare Diseases and Biobanks

    1. Front Matter

      Pages 95-95
    2. Facilitating Clinical Studies in Rare Diseases

      • Rashmi Gopal-Srivastava, Petra Kaufmann
      Pages 125-140
    3. Data Quality in Rare Diseases Registries

      • Yllka Kodra, Manuel Posada de la Paz, Alessio Coi, Michele Santoro, Fabrizio Bianchi, Faisal Ahmed et al.
      Pages 149-164
    4. Preparing Data at the Source to Foster Interoperability across Rare Disease Resources

      • Marco Roos, Estrella López Martin, Mark D. Wilkinson
      Pages 165-179
  5. Orphan Drugs and Therapies

    1. Front Matter

      Pages 181-181
    2. Post-approval Studies for Rare Disease Treatments and Orphan Drugs

      • William C. Maier, Ronald A. Christensen, Patricia Anderson
      Pages 197-205
    3. Health Technology Assessment and Appraisal of Therapies for Rare Diseases

      • Georgi Iskrov, Tsonka Miteva-Katrandzhieva, Rumen Stefanov
      Pages 221-231
    4. New Therapeutic Uses for Existing Drugs

      • Bobbie Ann Austin, Ami D. Gadhia
      Pages 233-247
    5. Patient Empowerment and Involvement in Research

      • Lilisbeth Perestelo-Pérez, Amado Rivero-Santana, Analia Abt-Sacks, Ana Toledo-Chavarri, Noe Brito, Yolanda Álvarez-Pérez et al.
      Pages 249-264

About this book

This second edition of the book about Rare Diseases Epidemiology aims to highlight the progress of rare diseases research and related activities since the first volume published. As with the previous book, this update provides a comprehensive list of issues and adds new authors who are leaders in their different areas of expertise related to rare diseases at national and international levels.

Rare diseases and orphan drugs are challenges for patients and families but also for physicians, researchers, and policy-makers in both the public and private sectors. This book aims to help all of them to address topics like health care policies, societal issues and clinical and experimental research.

Readers will discover methods and procedures to address a variety of questions like cases of undiagnosed rare diseases, patient registries and biobanks, health care and public health approach to rare diseases, orphan drugs and new therapies, cost-effectiveness analyses, prevention, clinical and epidemiology of individual and groups of related rare diseases, novel advances in study design and data analyses, national and international policies and social issues. Within each one of these general issues,  advances, new challenges and opportunities to address significant health care issues are described across thirty-two chapters.

Editors and all authors providing chapters include globally recognized experts in different areas of rare diseases, including epidemiology, public health, health economics and pharmacology, statistics, and basic, clinical and translational research. People engaged in policy formulation decisions on rare diseases as well as patient representatives relate their own point of view about social constraints they live under on a daily basis. Renowned research investigators, highly-skilled clinicians, and recognized patient leaders  are included as contributing authors to this new book about rare diseases. In fact, two of the editors are the current President and President Elect of the International Conference on Rare Diseases and Orphan Drugs and the third one is a board member of this society.

The book has been written for all stakeholders but mainly for those involved in the many issues related to rare diseases. They can discover new ways for dealing with important matters related to the prevention, diagnosis, natural history, treatments, and research of rare diseases and the development of orphan products. 

Keywords

  • epidemiology
  • genotype-phenotype correlation
  • next generation sequencing
  • orphan drugs
  • rare diseases

Reviews

“This second edition provides an update on the rapidly evolving field of rare disease research since the 2010 publication of the definitive first edition. … The intended audience is clinicians, epidemiologists, and policymakers, as well as other professionals involved in rare diseases and research. The contributing authors are well versed in areas related to rare disease epidemiology, research, and health policy.” (Victoria L. Crabb, Doody's Book Reviews, October, 2018)

Editors and Affiliations

  • RDR and CIBERER, Instituto de Salud Carlos III, Madrid, Spain

    Manuel Posada de la Paz

  • Centro Nazionale Malattie Rare, Istituto Superiore di Sanita, Roma, Italy

    Domenica Taruscio

  • National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, USA

    Stephen C. Groft

About the editors

Manuel Posada, MD, PhD (Please expand as you feel appropriate) is a specialist in Internal Medicine and in Public Health and Preventive Medicine. He has considerable expertise in areas such as multivariate analyses, medical statistics and research methodology. In his current position as Director of the Institute of Rare Diseases Research (IIER), Institute of Health Carlos III he leads a broad range of rare diseases activities in Spain in areas such as epidemiological and public health research. Dr. Posada is also the Director of the National Biobank on Rare Diseases (ISCIII) and the National Rare Diseases Registry. Dr. Posada is an Independent expert of the Commission Expert Group of Rare Diseases (CEGRD), European Commission and a member of the Advisory Board of the European Commission Platform Rare Diseases Registration. He is currently the President of the International Conference of Orphan Drugs and Rare Diseases (ICORD)

Domenica Taruscio, M.D., is the Director of the Italian National Centre for Rare Diseases at the Italian National Institute of Health and of the National Rare Diseases Registry. She is a specialist in Histopathology and carried out post-doctoral studies in Human Genetics at Yale University (CT-USA) and in Bioethics. For decades, her efforts have been mainly directed to face the many and complex challenges posed by rare diseases and has addressed them from various facets: from science to society, from experimental research to public health, from training health professionals to the empowerment of patients and their families - having always at heart the quality of life of rare disease patients and of their families.

Stephen C. Groft, Pharm.D. is currently a Senior Advisor to the Director, National Center for Advancing Translational Sciences at the NIH, USA. He assisted in establishing the Office of Orphan Products Development at FDA in 1982 and served as the Director of NIH’s Office of Rare Diseases Research from 1993-2014 stimulating rare diseases research and developing information for patients, health care providers, research investigators, the biopharmaceutical industry, and the public about rare diseases, ongoing and completed research and clinical trials, and patient advocacy groups. Numerous initiatives were established in this role including the establishment of the Genetic and Rare Diseases Information Center, the International Rare Diseases Research Consortium the International Conference on Rare Diseases and Orphan Drugs, the Rare Diseases Clinical Research Network, assisted in the development of the Undiagnosed Diseases Program at NIH and the global Undiagnosed Diseases Network International, and developed common data elements for patient registries. ORDR co-sponsored numerous scientific conferences to assist in identifying research priorities and developing research agendas for the investigation of rare diseases.

Bibliographic Information

Buying options

eBook
USD 219.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-67144-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 279.99
Price excludes VAT (USA)
Hardcover Book
USD 279.99
Price excludes VAT (USA)